October 23, 2025 a 08:38 am
HOLX: Analysts Ratings - Hologic, Inc.
Hologic, Inc. has shown consistent performance in the healthcare sector, primarily focusing on women's health. Over recent months, there has been a notable shift with an increase in 'Hold' recommendations, suggesting a cautious market outlook. Despite this, the company's innovative diagnostic and medical imaging solutions remain a potential growth driver in the foreseeable future.
Historical Stock Grades
As of October 2025, analyst recommendations for Hologic, Inc. indicate a stable environment with a pronounced shift towards holding positions. This trend may reflect a market cautiousness amidst changing economic conditions.
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 6 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the preceding months, there's been a notable increase in 'Hold' ratings, amidst declining 'Strong Buy' and 'Buy' recommendations. This suggests analyst sentiment is turning more cautious.
- 'Hold' ratings increased significantly from 2 in early 2024 to 13 by October 2025.
- 'Strong Buy' and 'Buy' experienced a gradual decline since 2024.
- Overall, the total number of analyst recommendations has remained relatively stable.
Percentage Trends
In the last year, the distribution of analyst recommendations for Hologic, Inc. reflects growing caution. The trend indicates a shift from 'Buy' to 'Hold', highlighting uncertainty regarding short-term performance.
- October 2025: 'Strong Buy' (11%), 'Buy' (21%), 'Hold' (68%).
- This represents a marked departure from January 2025's higher concentration in 'Strong Buy' and 'Buy'.
- The net movement suggests increased market prudence and neutrality towards Hologic's stock performance.
Latest Analyst Recommendations
Recent analyst activity has trended towards maintaining or downgrading the stock, reflecting an overall neutral sentiment.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-22 | Market Perform | Outperform | Raymond James |
| 2025-10-22 | Neutral | Overweight | JP Morgan |
| 2025-10-22 | Equal Weight | Overweight | Stephens & Co. |
| 2025-10-21 | Market Perform | Market Perform | Leerink Partners |
| 2025-10-21 | Hold | Hold | Needham |
Analyst Recommendations with Change of Opinion
These recent changes indicate a cautious sentiment adjustment by analysts, often downgrading to more neutral or lower ratings.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-22 | Market Perform | Outperform | Raymond James |
| 2025-10-22 | Neutral | Overweight | JP Morgan |
| 2025-10-22 | Equal Weight | Overweight | Stephens & Co. |
| 2025-10-07 | Outperform | In Line | Evercore ISI Group |
| 2025-08-06 | Outperform | Sector Perform | RBC Capital |
Interpretation
The current sentiment indicates that while Hologic's past performance has been stable, there's growing uncertainty among analysts. This is evident from the increased number of 'Hold' ratings and downgraded recommendations. Despite these reservations, the lack of 'Sell' or 'Strong Sell' ratings indicates maintained interest in the company's long-term potential amidst market cautiousness.
Conclusion
Hologic, Inc. continues to hold a strong position in the women’s health sector with its comprehensive range of diagnostics and surgical products. While recent analyst sentiment has trended towards caution, the technological innovations and broad international reach suggest potential for future growth. Investors should weigh current market neutral stances against the long-term opportunities presented by the company's strategic positioning and ongoing product innovations.